Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...

32.7% (p=0.004 vs placebo) of F3-F4 patients treated with 600 mg icosabutate achieved ≥1-stage improvement in fibrosis without worsening of MASH versus 9.6% of placebo treated patients as ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

MASH is marked by lipid droplet accumulation in the liver, progressing from steatosis to inflammation and cell damage, ultimately leading to fibrosis, cirrhosis, and hepatocellular carcinoma.